China SXT Pharmaceuticals Inc.

SXTC | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.93

-$0.05 (-1.68%)

At close: Nov 5, 2026, 4:00 PM ET

$2.83

-$0.10 (-3.40%)

After-hours: Nov 5, 2026, 6:17 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.68%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

29.4

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #809/1024 (Top 79%)

Full Analysis

Key Statistics

Market Data

Market Cap $15.65K

1D Range

2.83 3.00

52W Range

1.93 24,000

Valuation (TTM)

PE 0

PB 0.00

EV/EBITDA 3.87

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $0.00

Cash Flow

FCF Yield -37869.6%

SBC Adj. FCF Yield -54540.7%

SBC Impact -44.0%

Margins

Gross Margin 17.1%

Operating Margin -996.1%

FCF Margin -561.8%

Growth (CAGR)

Revenue 3Y | 5Y -29.1% | -35.3%

Dil EPS 3Y | 5Y 31.0% | 77.0%

FCF 3Y | 5Y -64.3% | -36.0%

Returns

ROA -17.9%

ROE -24.9%

ROIC -26.8%

Financial Health

Net Cash

$27.11M

Current Ratio 7.93

Interest Coverage -169.69

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company of...

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Employees 56

IPO Date Jan 4, 2019

Website www.sxtchina.com

Fiscal Year April - March

Full Company Profile

Latest News

15 days ago · prnewswire.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on October 26, 2026.

16 days ago · prnewswire.com

China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termination letter agreement, the Company and the purchasers have terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement entered into in connection with the Offering.

27 days ago · globenewswire.com

Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

New York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of $12 million for its client China SXT Pharmaceuticals Inc.

29 days ago · prnewswire.com

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering. The Company also agreed to issue to the same investors 8,000,000 warrants (the "Warrants") with an exercise price of $1.50 per share.